Risk assessment of drug-induced QT prolongation

Australian Prescriber

Volumn 38, Issue 1, 2015, Pages 20-24

  Isbister, Geoffrey K ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Arrhythmia; Electrocardiography; QT interval; QT prolongation; Torsades de pointes

Indexed keywords

AMIODARONE; AMISULPRIDE; CHLORPROMAZINE; CIPROFLOXACIN; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; CYTOCHROME P450 3A4; DIPHENHYDRAMINE; DISOPYRAMIDE; DOLASETRON MESILATE; ERYTHROMYCIN; ESCITALOPRAM; FLUCONAZOLE; HALOPERIDOL; LITHIUM; LORATADINE; METHADONE; MOCLOBEMIDE; MOXIFLOXACIN; ONDANSETRON; PENTAMIDINE; QUETIAPINE; RISPERIDONE; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VORICONAZOLE; ZIPRASIDONE;

ACTION POTENTIAL; ARTICLE; CARDIAC CHANNELOPATHY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; FETUS HEART RATE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTHYROIDISM; JERVELL AND LANGE-NIELSEN SYNDROME; NOMOGRAM; QT PROLONGATION; RISK ASSESSMENT; ROMANO-WARD SYNDROME; SENSITIVITY AND SPECIFICITY; TORSADE DES POINTES;

EID: 84961289511     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2015.003     Document Type: Article

References (13)

1. Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol 2013;76:48-57.
2. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
3. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000;320:1158-9.
4. Roberts JD, Gollob MH. The genetic and clinical features of cardiac channelopathies. Future Cardiol 2010;6:491-506.
5. Newton-Cheh C, Larson MG, Corey DC, Benjamin EJ, Herbert AG, Levy D, et al. QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. Heart Rhythm 2005;2:277-84.
6. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001;24:323-51.
7. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
8. Berling I, Isbister GK, Calver L, Clunas S. Digital Holter measurement of QT prolongation in ziprasidone overdose. Clin Toxicol (Phila) 2011;49:694-6.
9. Isbister GK, Calver L, Van Gorp F, Stokes B, Page CB. Inter-rater reliability of manual QT measurement and prediction of abnormal QT,HR pairs. Clin Toxicol (Phila) 2009;47:884-8.
10. Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods 2002;48:3-9.
11. Isbister GK, Duffull SB. Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol 2009;24:174-80.
12. Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, et al. Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 2005;312:1-11.
13. Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 2007;100:609-15.